MGC Pharmaceuticals Reports Solid Growth in October

  • Oct 16, 2019 AEDT
  • Team Kalkine

MGC Pharmaceuticals Ltd (ASX: MXC) has reported that the number of patients being prescribed its cannabinoid medicines has now passed the key milestone of 600 in Australia & the United Kingdom.

  • Prescriptions were 400 at the end of September.
  • Average 19 prescriptions issued per day to date in October.
  • MXC is working closely with distributors to onboard further clinics.

By 12:39 PM AEST, MXC was quoting at $0.036, up by 5.9% from the last close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK